HanAll Biopharma, Conclusion of Joint Development Contract for New Medicine of Dry Eye Disease with Daewoong Pharmaceutical
HanAll Biopharma, Conclusion of Joint Development Contract for New Medicine of Dry Eye Disease with ..
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-control..
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program